Aerie Pharmaceuticals, Inc.

Shareholder Securities Fraud Litigation

Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Aerie Pharmaceuticals, Inc. (NASDAQ GM: AERI)

Rigrodsky & Long, P.A., including former Special Assistant United States Attorney, Timothy J. MacFall, announces that a complaint has been filed in the United States District Court for the District of New Jersey on behalf of all persons or entities that purchased the common stock of Aerie Pharmaceuticals, Inc. (“Aerie” or the “Company”) (NASDAQ GM: AERI) between August 6, 2014 and April 23, 2015, inclusive (the “Class Period”), alleging violations of the Securities Exchange Act of 1934 against the Company and certain of its officers (the “Complaint”).

If you purchased shares of Aerie during the Class Period, or purchased shares prior to the Class Period and still hold Aerie,  and wish to discuss this action or have any questions concerning this notice or your rights or interests, please contact Timothy J. MacFall, Esquire or Peter Allocco of Rigrodsky & Long, P.A., 2 Righter Parkway, Suite 120, Wilmington, DE 19803 at (888) 969-4242; by e-mail to

The Complaint alleges that throughout the Class Period, defendants made materially false and misleading statements, and omitted materially adverse facts, about the Company’s business, operations and prospects.  Specifically, the Complaint alleges that the defendants concealed from the investing public that the prospects for the Phase 3 study for its lead product candidate, Rhopressa, were materially false and misleading as Rhopressa was performing as well as timolol, the most widely used comparator in registration trials for glaucoma, and would not lead to commercial success.  As a result of defendants’ alleged false and misleading statements, the Company’s stock traded at artificially inflated prices during the Class Period.

According to the Complaint, on April 23, 2015, after the market closed, Aerie issued a press release announcing the results of its first Phase 3 registration trial for Rhopressa.  According to the release, “[t]he trial did not meet its primary efficacy endpoint of demonstrating non-inferiority of intraocular pressure lowering for once-daily Rhopressa™ compared to twice-daily timolol, the most widely used comparator in registration trials for glaucoma.”

On this news, shares in Aerie dropped over 63%, closing at $12.87 per share on April 24, 2015, on heavy trading volume.

If you wish to serve as lead plaintiff, you must move the Court no later than June 29, 2015.  A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.  In order to be appointed lead plaintiff, the Court must determine that the class member’s claim is typical of the claims of other class members, and that the class member will adequately represent the class.  Your ability to share in any recovery is not, however, affected by the decision whether or not to serve as a lead plaintiff.  Any member of the proposed class may move the court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member.

While Rigrodsky & Long, P.A. did not file the Complaint in this matter, the firm, with offices in Wilmington, Delaware and Garden City, New York, regularly litigates securities class, derivative and direct actions, shareholder rights litigation and corporate governance litigation, including claims for breach of fiduciary duty and proxy violations in the Delaware Court of Chancery and in state and federal courts throughout the United States.

Attorney advertising.  Prior results do not guarantee a similar outcome.